BridgeBio Pharma has a consensus price target of $63.94, indicating a potential upside of 23.11%. Given BridgeBio Pharma's stronger consensus rating and higher possible upside, analysts plainly believe BridgeBio Pharma is more favorable than Targeted Medical Pharma.